Jan 7 (Reuters) - Immutep Ltd (IMM) :
- ENTERS CLINICAL TRIAL COLLABORATION WITH CYTLIMIC TO TEST EFTILAGIMOD ALPHA
- IMMUTEP IS ELIGIBLE TO RECEIVE UP TO US$4.5 MILLION IN MILESTONE PAYMENTS UPON ACHIEVEMENT OF MILESTONES BY CYTLIMIC
- ENTERED INTO A SUPPLY AGREEMENT TO PROVIDE EFTI TO CYTLIMIC FOR MANUFACTURE OF CYT001
- ENTERED SERVICE AGREEMENT WHERE IMMUTEP WILL PROVIDE TECHNICAL SUPPORT SERVICES TO CYTLIMIC DURING DEVELOPMENT & COMMERCIALISATION OF CYT00
News: IMM Immutep Enters Clinical Trial Collaboration, Supply And Service Agreement With CYTLIMIC
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
28.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $486.6M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 42858 | 29.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 27.5¢ | 2000 | 1 |
View Market Depth
| Last trade - 09.27am 22/11/2024 (20 minute delay) ? |
| IMM (ASX) Chart |
Day chart unavailable
